Historical Valuation
Vir Biotechnology Inc (VIR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 30.71 is considered Undervalued compared with the five-year average of -6.18. The fair price of Vir Biotechnology Inc (VIR) is between 6.86 to 13.72 according to relative valuation methord. Compared to the current price of 5.85 USD , Vir Biotechnology Inc is Undervalued By 14.7%.
Relative Value
Fair Zone
6.86-13.72
Current Price：5.85
14.7%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Vir Biotechnology Inc (VIR) has a current Price-to-Book (P/B) ratio of 1.04. Compared to its 3-year average P/B ratio of 1.00 , the current P/B ratio is approximately 3.92% higher. Relative to its 5-year average P/B ratio of 2.59, the current P/B ratio is about -59.88% higher. Vir Biotechnology Inc (VIR) has a Forward Free Cash Flow (FCF) yield of approximately -55.67%. Compared to its 3-year average FCF yield of -35.69%, the current FCF yield is approximately 55.97% lower. Relative to its 5-year average FCF yield of -16.13% , the current FCF yield is about 245.02% lower.
P/B
Median3y
1.00
Median5y
2.59
FCF Yield
Median3y
-35.69
Median5y
-16.13
Competitors Valuation Multiple
AI Analysis for VIR
The average P/S ratio for VIR competitors is 145.12, providing a benchmark for relative valuation. Vir Biotechnology Inc Corp (VIR.O) exhibits a P/S ratio of 30.71, which is -78.84% above the industry average. Given its robust revenue growth of -89.92%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for VIR
1Y
3Y
5Y
Market capitalization of VIR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VIR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VIR currently overvalued or undervalued?
Vir Biotechnology Inc (VIR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 30.71 is considered Undervalued compared with the five-year average of -6.18. The fair price of Vir Biotechnology Inc (VIR) is between 6.86 to 13.72 according to relative valuation methord. Compared to the current price of 5.85 USD , Vir Biotechnology Inc is Undervalued By 14.70% .
What is Vir Biotechnology Inc (VIR) fair value?
VIR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Vir Biotechnology Inc (VIR) is between 6.86 to 13.72 according to relative valuation methord.
How does VIR's valuation metrics compare to the industry average?
The average P/S ratio for VIR's competitors is 145.12, providing a benchmark for relative valuation. Vir Biotechnology Inc Corp (VIR) exhibits a P/S ratio of 30.71, which is -78.84% above the industry average. Given its robust revenue growth of -89.92%, this premium appears unsustainable.
What is the current P/B ratio for Vir Biotechnology Inc (VIR) as of Jan 10 2026?
As of Jan 10 2026, Vir Biotechnology Inc (VIR) has a P/B ratio of 1.04. This indicates that the market values VIR at 1.04 times its book value.
What is the current FCF Yield for Vir Biotechnology Inc (VIR) as of Jan 10 2026?
As of Jan 10 2026, Vir Biotechnology Inc (VIR) has a FCF Yield of -55.67%. This means that for every dollar of Vir Biotechnology Inc’s market capitalization, the company generates -55.67 cents in free cash flow.
What is the current Forward P/E ratio for Vir Biotechnology Inc (VIR) as of Jan 10 2026?
As of Jan 10 2026, Vir Biotechnology Inc (VIR) has a Forward P/E ratio of -2.69. This means the market is willing to pay $-2.69 for every dollar of Vir Biotechnology Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Vir Biotechnology Inc (VIR) as of Jan 10 2026?
As of Jan 10 2026, Vir Biotechnology Inc (VIR) has a Forward P/S ratio of 30.71. This means the market is valuing VIR at $30.71 for every dollar of expected revenue over the next 12 months.